Ovid Therapeutics names new CFO and CBO in leadership reshuffle
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
July 8, 2026 7:00 AM EDTKevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business OfficerCharles Carter promoted to Chief Financial Officer, reflecting his strong leadership and oversight of Ovids financial operations, following Jeffrey Ronas transition to an advisory roleEliseo Salinas, MD, joined as Executive R&D Advisor, building on a distinguished career leading the development of multiple, breakthrough neurologic and psychiatric... More
